News | Treatment Planning | February 16, 2018

Mitchell Cancer Institute Selects RayStation for TomoTherapy Planning

Cancer center at the University of South Alabama will also use RayStation for CyberKnife System treatment planning when the functionality is added in the future

Mitchell Cancer Institute Selects RayStation for TomoTherapy Planning

February 16, 2018 — The University of South Alabama Mitchell Cancer Institute (MCI) in Mobile, Ala., has selected RayStation as its treatment planning system for the TomoTherapy System. The center also treats patients using a CyberKnife System and will use RayStation for this in the future.

MCI’s radiation therapy service is equipped with Accuray´s CyberKnife and TomoTherapy System, as well as a 64-slice positron emission tomography/computed tomography (PET/CT) scanner. The center was initially interested in RayStation’s forthcoming support for the CyberKnife System, but saw that the system could meet all of its treatment planning needs into the future, including the TomoTherapy System.

Founded in 2000, MCI provides cancer treatment in three locations — MCI headquarters in Mobile, the MCI Kilborn Clinic in Fairhope and Monroe County Hospital in Monroeville — serving a potential catchment population of more than 4.1 million people.

Weisi Yan, M.D., Ph.D., director of the CyberKnife Program at MCI, said, “We were very impressed by the capabilities and user-friendliness of RayStation. As a leading-edge treatment center, we need the best possible technology in order to deliver outstanding care and maximize efficiency. RayStation will help us to achieve our goals.”

Hal Hopper, manager of MCI’s Department of Radiation Oncology, said, “RayStation is fast and effective in planning treatments for all possible techniques we are likely to offer. It is much less labor-intensive than other systems we have used. With RayStation, the physician can choose the best course of treatment more quickly.”

For more information: www.raysearchlabs.com

 

Related Content

Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly welcomes Siemens Healthineers AG’s acquisition of a 100 percent stake in Varian Medical Systems, Inc., a U.S. company active in the area of cancer research and therapy.

Getty Images

News | Radiology Business | August 03, 2020
August 3, 2020 — Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly wel
JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

Table 1. JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

News | Coronavirus (COVID-19) | July 31, 2020
July 31, 2020 — An article published in JAMA...
It has been estimated that the overwhelming focus on COVID-19 could cause up to 35,000 excess cancer deaths in the UK during the next 12 months, and  Zegami, the Oxford University data visualization spin-out which has worked on several projects focused on the detection, diagnosis, or management of cancer, is calling for greater use of technology to speed up the process of diagnosis and treatment.

Getty Images

News | Radiation Oncology | July 29, 2020
July 29, 2020 — It has been estimated that the overwhelming focus on...
In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.  http://jnm.snmjournals.org/content/early/2020/07/16/jnumed.120.249748.full.pdf+html

In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.

 

News | Coronavirus (COVID-19) | July 22, 2020 | Dave Fornell, Editor
July 22, 2020 — One of the first studies has been published that looks at the use of...
World's largest radiation oncology meeting will offer full conference on interactive platform October 25-28, 2020
News | ASTRO | July 09, 2020
July 9, 2020 — Registration opens today for the American Society for Radiation Oncology's (...
At the American Association of Physicists in Medicine (AAPM) 2019 meeting, new artificial intelligence (AI) software to assist with radiotherapy treatment planning systems was highlighted. The goal of the AI-based systems is to save staff time, while still allowing clinicians to do the final patient review. 
Feature | Treatment Planning | July 08, 2020 | By Melinda Taschetta-Millane
At the American Association of Physicists in Medicine (AAPM) 201
Radiotherapy has been used to treat cancers for more than a century and continues to be utilized in cancer treatment plans today. Since the introduction of radiotherapy, clinicians have been working tirelessly to further refine treatments to better target cancer.
Feature | Radiation Therapy | July 06, 2020 | By Yves Archambault
Everything has room for improvement, right? Right. When it comes to cancer care, it is no different.
Proton therapy has evolved, and future predictions include smaller systems, more sophisticated proton dosimetry and devices that manipulate the proton beam
Feature | Proton Therapy | July 06, 2020 | By Minesh Mehta, M.D.
The field of proton...